Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field of neoantigen-targeted therapies and dedicated to transforming the treatment of each patient’s cancer by directing the immune system towards neoantigens. We have pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies using two distinct approaches. In NEON / ONE, these neoantigens are specific to each individual. In NEON / SELECT, these neoantigens are shared across subsets of patients and tumor types. Our most advanced product candidate is NEO‑PV‑01, a personal neoantigen vaccine, that is currently being evaluated in a Phase 1b open‑label clinical trial for patients with metastatic melanoma, non‑small cell lung cancer or bladder cancer.
Copyright West LLC. Minimum 15 minutes delayed.
Mar 11, 2019 at 4:50 PM EDT
Feb 28, 2019 at 9:00 AM EST
Nov 9, 2018 at 6:00 PM EST
March 11, 2019Neon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
March 4, 2019Neon Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference
February 27, 2019Neon Therapeutics to Present at the American Association for Cancer Research Annual Meeting